Related Experiment Videos
Locking the dimeric GABA(B) G-protein-coupled receptor in its active state
Julie Kniazeff1, Pierre-Philippe Saintot, Cyril Goudet
1Laboratory for Functional Genomic, Department of Molecular Pharmacology, Centre National de la Recherche Scientifique Unité Propre de Recherche-2580, Montpellier Cedex 5, France.
Summary
Researchers locked the inhibitory GABA(B) receptor in an active state using a disulfide bridge, demonstrating that the closed binding domain is sufficient for constitutive activity in this G-protein-coupled receptor.
Area of Science:
- Neuroscience
- Molecular Biology
- Biochemistry
Background:
- G-protein-coupled receptors (GPCRs) are crucial for cell communication in the central nervous system (CNS).
- GPCRs exist in dynamic inactive and active conformations, typically stabilized by agonists.
- The role of individual protomers in the activation of dimeric GPCRs remains largely unknown.
Purpose of the Study:
- To investigate the role of the GABA(B1) subunit's binding domain conformation in the activation of the heterodimeric GABA(B) receptor.
- To determine if a GPCR can be locked into a constitutively active state.
Main Methods:
- Site-directed mutagenesis to introduce cysteines in the GABA(B1) subunit.
- Formation of a disulfide bridge to stabilize the binding domain in a closed conformation.
- Assessment of receptor activity, agonist binding, and antagonist inhibition.
Main Results:
- A disulfide bridge successfully locked the heterodimeric GABA(B) receptor in a constitutively active state.
- The locked receptor exhibited sustained activity independent of agonists.
- Reversibility was achieved via reduction with dithiothreitol, restoring normal agonist and antagonist responses.
Conclusions:
- The closed conformation of the GABA(B1) binding domain is sufficient to constitutively activate the heterodimeric GABA(B) receptor.
- This study provides the first evidence of locking a GPCR into a stable active conformation.
- Understanding GPCR conformational dynamics offers new therapeutic targets for CNS disorders.